ALX Oncology Holdings Inc. Files 2023 Annual Report on Form 10-K
Ticker: ALXO · Form: 10-K · Filed: Mar 7, 2024 · CIK: 1810182
Sentiment: neutral
Topics: 10-K, ALX Oncology, Financial Report, Biotechnology, R&D Expenses
TL;DR
<b>ALX Oncology Holdings Inc. has filed its 2023 10-K, outlining its business operations, financial agreements, and R&D activities.</b>
AI Summary
ALX ONCOLOGY HOLDINGS INC (ALXO) filed a Annual Report (10-K) with the SEC on March 7, 2024. ALX Oncology Holdings Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The filing details various agreements including commercial antibody agreements with Crystal Bioscience Inc. and commercial license agreements with Selexis SA. The company's financial activities include secured term loan facilities with Oxford Finance and Silicon Valley Bank, with specific tranches mentioned (Tranche B, Tranche D). Research and development expenses were incurred across fiscal years 2021, 2022, and 2023. Key dates include the company's IPO on July 21, 2020, and various financing and agreement dates throughout 2021, 2022, and 2023.
Why It Matters
For investors and stakeholders tracking ALX ONCOLOGY HOLDINGS INC, this filing contains several important signals. This 10-K provides a comprehensive overview of ALX Oncology's financial health, debt obligations, and strategic partnerships, crucial for investors assessing the company's stability and growth potential. The detailed breakdown of agreements and financing activities, including loan facilities and equity offerings, offers insight into the company's capital structure and its ability to fund ongoing research and development in the competitive oncology sector.
Risk Assessment
Risk Level: medium — ALX ONCOLOGY HOLDINGS INC shows moderate risk based on this filing. The company's financial disclosures, including debt agreements and R&D expenses, indicate a typical profile for a clinical-stage biopharmaceutical company, suggesting a medium level of financial risk associated with its development stage.
Analyst Insight
Investors should review the detailed financial statements and risk factors in the 10-K to understand ALX Oncology's current financial position and future funding needs.
Key Numbers
- 2023-12-31 — Fiscal Year End (Period of report)
- 2024-03-07 — Filing Date (Date of filing)
- 2020-07-21 — IPO Date (Initial Public Offering)
Key Players & Entities
- ALX ONCOLOGY HOLDINGS INC (company) — Filer name
- Crystal Bioscience Inc (company) — Party to commercial antibody agreement
- Selexis SA (company) — Party to commercial license agreement
- Oxford Finance (company) — Lender in secured term loan facility
- Silicon Valley Bank (company) — Lender in secured term loan facility
- Stanford Junior University (company) — Party to exclusive equity agreement
- Scali Bio Inc (company) — Mentioned in relation to an agreement
FAQ
When did ALX ONCOLOGY HOLDINGS INC file this 10-K?
ALX ONCOLOGY HOLDINGS INC filed this Annual Report (10-K) with the SEC on March 7, 2024.
What is a 10-K filing?
A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by ALX ONCOLOGY HOLDINGS INC (ALXO).
Where can I read the original 10-K filing from ALX ONCOLOGY HOLDINGS INC?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by ALX ONCOLOGY HOLDINGS INC.
What are the key takeaways from ALX ONCOLOGY HOLDINGS INC's 10-K?
ALX ONCOLOGY HOLDINGS INC filed this 10-K on March 7, 2024. Key takeaways: ALX Oncology Holdings Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023.. The filing details various agreements including commercial antibody agreements with Crystal Bioscience Inc. and commercial license agreements with Selexis SA.. The company's financial activities include secured term loan facilities with Oxford Finance and Silicon Valley Bank, with specific tranches mentioned (Tranche B, Tranche D)..
Is ALX ONCOLOGY HOLDINGS INC a risky investment based on this filing?
Based on this 10-K, ALX ONCOLOGY HOLDINGS INC presents a moderate-risk profile. The company's financial disclosures, including debt agreements and R&D expenses, indicate a typical profile for a clinical-stage biopharmaceutical company, suggesting a medium level of financial risk associated with its development stage.
What should investors do after reading ALX ONCOLOGY HOLDINGS INC's 10-K?
Investors should review the detailed financial statements and risk factors in the 10-K to understand ALX Oncology's current financial position and future funding needs. The overall sentiment from this filing is neutral.
Risk Factors
- Financing and Liquidity [high — financial]: The company's ability to continue as a going concern is dependent on its ability to secure additional financing and achieve profitability.
- Regulatory Approval Process [high — regulatory]: The development and commercialization of oncology drugs are subject to extensive regulatory review and approval processes by agencies like the FDA.
- Competition [medium — market]: The oncology market is highly competitive, with numerous companies developing novel therapies.
- Clinical Trial Success [high — operational]: The success of the company's product candidates relies heavily on the outcomes of ongoing and future clinical trials.
Key Dates
- 2023-12-31: Fiscal Year End — Reporting period for the 10-K
- 2024-03-07: Filing Date — Date the 10-K was officially submitted
- 2020-07-21: IPO — Company's Initial Public Offering date
Filing Stats: 4,326 words · 17 min read · ~14 pages · Grade level 17.9 · Accepted 2024-03-07 16:11:48
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ALXO The Nasdaq Global Se
Filing Documents
- alxo-20231231.htm (10-K) — 3246KB
- alxo-ex4_3.htm (EX-4.3) — 38KB
- alxo-ex21_1.htm (EX-21.1) — 6KB
- alxo-ex23_1.htm (EX-23.1) — 2KB
- alxo-ex31_1.htm (EX-31.1) — 15KB
- alxo-ex31_2.htm (EX-31.2) — 15KB
- alxo-ex32_1.htm (EX-32.1) — 8KB
- alxo-ex32_2.htm (EX-32.2) — 8KB
- alxo-ex97_1.htm (EX-97.1) — 46KB
- img50887369_0.jpg (GRAPHIC) — 113KB
- img50887369_1.jpg (GRAPHIC) — 35KB
- img50887369_2.jpg (GRAPHIC) — 65KB
- img50887369_3.jpg (GRAPHIC) — 75KB
- img50887369_4.jpg (GRAPHIC) — 58KB
- img50887369_5.jpg (GRAPHIC) — 176KB
- img50887369_6.jpg (GRAPHIC) — 41KB
- img50887369_7.jpg (GRAPHIC) — 49KB
- img50887369_8.jpg (GRAPHIC) — 137KB
- img50887369_9.jpg (GRAPHIC) — 15KB
- img50887369_10.jpg (GRAPHIC) — 5KB
- img50887369_11.jpg (GRAPHIC) — 51KB
- img50887369_12.jpg (GRAPHIC) — 35KB
- img50887369_13.jpg (GRAPHIC) — 71KB
- 0000950170-24-027955.txt ( ) — 14568KB
- alxo-20231231.xsd (EX-101.SCH) — 1554KB
- alxo-20231231_htm.xml (XML) — 2162KB
Business
Business 1 Item 1A.
Risk Factors
Risk Factors 36 Item 1B. Unresolved Staff Comments 83 Item 1C. Cybersecurity 83 Item 2.
Properties
Properties 84 Item 3.
Legal Proceedings
Legal Proceedings 84 Item 4. Mine Safety Disclosures 84 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 85 Item 6. [Reserved] 85 Item 7.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 86 Item 7A.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 97 Item 8.
Financial Statements and Supplementary Data
Financial Statements and Supplementary Data 98 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 128 Item 9A.
Controls and Procedures
Controls and Procedures 128 Item 9B. Other Information 128 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 129 PART III Item 10. Directors, Executive Officers and Corporate Governance 130 Item 11.
Executive Compensation
Executive Compensation 130 Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 130 Item 13. Certain Relationships and Related Transactions, and Director Independence 130 Item 14. Principal Accounting Fees and Services 130 PART IV Item 15. Exhibits, Financial Statement Schedules 131 Item 16. Form 10-K Summary 134
SIGNATURES
SIGNATURES 135 iii PART I
BUSINESS
BUSINESS Overview We are a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint and bridge the innate and adaptive immune system. Our lead product candidate, the CD47 blocker evorpacept, is currently in multiple Phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a "don't eat me" signal to evade macrophage phagocytosis or as a "don't activate T-cells" signal that prevents activation of T-cells by dendritic cells. We are developing evorpacept to be a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Anti-cancer agents, including many chemotherapies, other small molecules and anti-cancer antibodies, can stimulate immune cells such as macrophages to engulf and kill cancer cells, a process known as phagocytosis, by providing so-called "eat me" signals on cancer cells. In response, cancer cells frequently overexpress CD47 to counteract these "eat me" signals. As a result, high expression of CD47 on cancer cells has been associated with reduced patient survival in multiple cancers. The therapeutic blockade of CD47 in combination with an "eat me" signal enables the immune system to detect and phagocytose cancer cells. However, healthy blood cells and nearly all other cells in the body also express CD47 as a way to protect against pathologic phagocytosis by immune cells. There have been a number of approaches to blocking CD47, including monoclonal antibodies and fusion proteins that include an active Fc region. These approaches have encountered limitations, including limited dosing and therapeutic window, limited ability to combine with other anti-cancer agents, limited efficacy in solid tumors and limited indications due to patient selection, that have challenged their ability to maximize the full potential of CD4